Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Myriad Genetics Inc Sees FY 2013 Guidance At High End Of Prior Range


Friday, 1 Mar 2013 08:00pm EST 

Myriad Genetics Inc announced that it currently expects total revenues for fiscal 2013 to be at the high end of the $575 million to $585 million previous guidance range and diluted earnings per share (EPS) to be at the high end of the $1.55 to $1.58 previous guidance range. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $583 million and EPS of $1.57 for fiscal 2013. 

Related Company News

Company Quote

33.2
-0.05 -0.15%
26 Nov 2014